title: Interview with Dr Bernard Pécoul, Executive Director of the Drugs for Neglected Diseases Initiative.
abstract: A significant number of product-development partnerships have arisen in the past 10 years to tackle diseases that mainly affect developing countries. With their coherent research and development leadership, they have become key players in identifying gaps and overcoming bottlenecks in order to deliver medicines to those who need them most in the developing world. Dr Bernard Pécoul is the Executive Director of one such partnership, the Drugs for Neglected Diseases Initiative (DNDi). Under his leadership, the DNDi has built the largest and most robust R&D portfolio for three of the most neglected diseases. He speaks to Future Medicinal Chemistry about challenges facing neglected disease R&D and the DNDi's ongoing work.
authors.forename: Bernard
authors.initials: B
authors.lastname: Pécoul
mesh_terms: D000047:Academies and Institutes / Q000458:organization & administration; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000517:prevention & control; D058069:Neglected Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012106:Research; D014330:Tropical Medicine; D014344:Trypanocidal Agents / Q000627:therapeutic use; D014353:Trypanosomiasis, African / Q000188:drug therapy
chemical_list: D014344:Trypanocidal Agents